Leaders of a new dermatology-focused biotech, which has launched with 14 development programs in its pipeline, explain the rationale behind the company creation and the ideal exit scenario.

Having adopted a similar model to set up Centessa, investment firm Medicxi is merging six of its portfolio companies to create an ambitious immuno-dermatology group.

FDA’s Peter Marks says there may be a way to reduce the regulatory burden for pancreatic islet cell treatment for diabetes. Researchers in Canada and Europe note access to therapy is limited in the US since FDA regulates islet cells as a drug while other countries regulate them as a tissue or organ.

Plus deals involving Bristol Myers Squibb/Avidity, Aexon/NLS, Boehringer Ingelheim/Phenomic AI, AnaptysBio/Centessa and Biodexa/Adhera/Melior.